Form 4 for PMVP PMV Pharmaceuticals, Inc.
Accepted 2025-10-29 00:00:00 ET · period of report 2025-10-27 · accession 0001341642-25-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-10-29 | 2025-10-27 | PMVP | Mack David Henry | Pres, CEO, Dir | M - OptEx | $1.37 | +220.6K | 451.1K | +96% | +$302.3K |
| D | 2025-10-29 | 2025-10-27 | PMVP | Mack David Henry | Pres, CEO, Dir | M - OptEx | $0.00 | -220.6K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-10-27 | M | A | 220,643 | $1.37 | 451,109 | D | — | — | (F1) Excludes 305,667 shares previously reported as held directly by the reporting person which were re-registered on August 13, 2025 and are now held of record by the Mack-Mulligan Revocable Trust (the "Revocable Trust"). |
| 2 | Derivative | Employee Stock Option (right to buy) | 2025-10-27 | M | D | 220,643 | $0.00 | 0 | D | $1.37 · — to 2026-11-16 | 220,643 Common Stock | (F6) The shares subject to the option are fully vested and immediately exercisable. |